Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel Endorses Genzyme’s Synvisc-One Knee Therapy

This article was originally published in The Gray Sheet

Executive Summary

FDA's Orthopedic and Rehabilitation Devices advisory panel voted unanimously last week to recommend approval of Genzyme's PMA supplement for a single-dose version of its hyaluronic acid-based osteoarthritis knee therapy

You may also be interested in...



Q-Med's Durolane Knee Therapy Not Approvable, Needs New Trial - FDA Panel

Q-Med's Durolane hyaluronic acid treatment for knee osteoarthritis needs a new randomized trial prior to FDA approval, according to the agency's Orthopedic and Rehabilitation Devices Panel

Q-Med's Durolane Knee Therapy Not Approvable, Needs New Trial - FDA Panel

Q-Med's Durolane hyaluronic acid treatment for knee osteoarthritis needs a new randomized trial prior to FDA approval, according to the agency's Orthopedic and Rehabilitation Devices Panel

Q-Med's Durolane Knee Therapy, DePuy's CoMplete Hip Go To Panel

FDA's Orthopedic and Rehabilitation Devices panel will meet Aug. 19 to assess Q-Med's PMA application for its Durolane single-injection, hyaluronic acid-based treatment for knee osteoarthritis

Related Content

UsernamePublicRestriction

Register

MT026890

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel